Total Voting Rights & Block Listing Return

RNS Number : 9342D
Ergomed plc
01 July 2019
 

 PRESS RELEASE

 

 

Date: 1 July 2019

Ergomed plc

 

TOTAL VOTING RIGHTS AND BLOCK LISTING RETURN

 

 

Total Voting Rights

 

In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTRs), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 30 June 2019 consisted of 46,717,412 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right. 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

 

 

Block Listing Six Monthly Return

 

 

Name of applicant:

Ergomed plc

Name of scheme:

Ergomed plc Long Term Incentive Plan

Period of return:

From:

1 January 2019

To:

30 June 2019

Balance of unallotted securities under scheme(s) from previous return:

1,745,000

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

542,164

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

1,202,836

Number and class of securities originally admitted and the date of admission

1,800,000 ordinary shares of 1p each - 2 July 2018

Total number of securities in issue at the end of the period

46,717,412 ordinary shares of 1p each

 

Name of contact:

Nick Blech - Deputy CFO

Telephone number of contact:

+44 (0)7768 547372

 

 Enquiries:

Ergomed plc

Tel: +44 (0) 1483 503205

Richard Barfield (Chief Financial Officer)

 

 




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield (Nominated Adviser)


James Black (Broker)

 


Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Matthew Neal / Olivia Manser

 

 

ergomed@consilium-comms.com



MC-Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSDFEFSFUSELM

Companies

Ergomed (ERGO)
UK 100

Latest directors dealings